Qiagen launches NeuMoDx multiplex test in Industry News Create PDFNeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage is CE-IVD marked and has been submitted to the FDA for emergency use authorization. Pages: 1 2 Qiagen 2020-11-17 CAP TODAY Previous Post Next Post
CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
